“Our purpose as an association, aligned with that of the WHO, is to achieve 70% survival in cancer in 2030 and, for this, research is necessary”, as explained by Professor Antonio Llombart, vice president of the Associated Board of the AECC of Valencia.
In this fifth edition of the grants for pre-doctoral researchers, young researchers will develop their projects in leading entities in this field, such as the Prince Felipe Research Center (CIPF), the Foundation for the Promotion of Health and Biomedical Research of the Community Valenciana (Fisabio), the Polytechnic University of Valencia (UPV) and the University of Valencia (UV).
The grants have a duration of three years, extendable for up to one more year, and a total endowment that can reach up to 88,000 euros -22,000 per year- and that is possible thanks to the Runcáncer circuit of races and solidarity marches. Since 2016, 24 young researchers are or have already enjoyed this program, managed by the Scientific Foundation of the Spanish Association Against Cancer.
“Our young researchers have reaped significant findings that have helped in the early detection and treatment of a disease that affects more than 282,000 people every year. For this reason we continue to bet on this type of aid and we continue to demand more funding to promote the projects “, added Professor Antonio Llombart.
In addition to the commitment to young talent, the Associated Board of the AECC in Valencia, through the Association’s Scientific Foundation, has financed this year with 360,000 euros two new research projects in pediatric cancer and breast cancer, which are They will be held at the Prince Felipe Research Center, with a duration of up to four years.
The first of them, led by Dr. Inmaculada Conejos-Sánchez, addresses the design and development of a therapy aimed at the treatment and monitoring of solid pediatric tumors with a worse prognosis or lack of effective treatments, with an endowment of up to 200,000 euros, 50,000 euros by year.
The second of them, promoted by Dr. Federico Lucantoni with an endowment of up to 160,000 euros, focuses on the achievement of new therapies for triple negative breast cancer, a highly aggressive and heterogeneous type of cancer with no effective treatment options available clinic.
The Association, through initiatives such as pre-doctoral grants or the programs of the Scientific Foundation, continues to invest in research to combat this disease and improve the quality of life of patients.
– .
